What is RNAC's revenue growth forecast for 2024-2024?
(NASDAQ: RNAC) Cartesian Therapeutics's forecast annual revenue growth rate of 24.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.89%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.82%.
Cartesian Therapeutics's revenue in 2024 is $34,533,000.
In 2024, RNAC is forecast to generate $9,552,817,402 in revenue, with the lowest revenue forecast at $3,104,083,640 and the highest revenue forecast at $16,001,551,164.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.